Merck Starts To Suspend Worldwide Availability Of Tredaptive

In the wake of the negative HPS2-THRIVE study announced last month, Merck said today that it was beginning to suspend the worldwide availability of Tredaptive, its combination of extended-release niacin and laropiprant.

Source: Forbes.com Healthcare News - January 11, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news